Cooking Fumes Raise Lung Cancer Risk in Never Smokers
A systematic review found that higher lifetime exposure to cooking oil fumes was associated with an increased risk for lung cancer in never-smoking women in high-income countries.
METHODOLOGY:
Researchers conducted a systematic review to study the relationship between exposure to cooking fumes, a type of household air pollution, and lung cancer in never smokers in high-income countries.
The analysis included three case-control studies comprising 3734 participants, with all studies focusing on Chinese women using traditional cooking methods.
TAKEAWAY:
Higher cooking time-years (> 160) were associated with an increased risk for lung cancer (odds ratio [OR], 3.17; 95% CI, 1.34-7.68).
Compared with cooking dish-years ≤ 50, cooking dish-years > 200 conferred an OR of 8.09 (95% CI, 2.57-25.45).
Deep frying was associated with the highest risk (per 10 dish-years), with an OR of 2.56 (95% CI, 1.31-5.00), followed by pan frying (OR, 1.47; 95% CI, 1.27-1.69) and stir frying (OR, 1.12; 95% CI, 1.07-1.18).
Cooking three meals per day was associated with a threefold higher risk for lung cancer than cooking one meal per day (OR, 3.1; 95% CI, 1.6-6.2).
Ventilation hoods showed a protective effect against lung cancer in never smokers (adjusted OR, 0.49; 95% CI, 0.32-0.76).
IN PRACTICE:
"Exposure to cooking fumes is linked to lung cancer due to the levels of carcinogens that can be produced during the heating of oils to high temperatures. VOCs [volatile organic compounds] which are generated by cooking oils have been shown to be mutagenic, containing PACs [polycyclic aromatic hydrocarbons], aldehydes, carbonyl compounds and other mutagens," the authors of the study wrote.
SOURCE:
This study was led by Bría Joyce McAllister, University of Leicester College of Life Sciences, Leicester, England. It was published online on June 20, 2025, in BMJ Open.
LIMITATIONS:
All three studies relied on questionnaires and participant recollection rather than active monitoring of household air pollutant concentrations while cooking. The questionnaires used were not included in the publications, potentially limiting replication. Additionally, none of the studies accounted for the effects of outdoor air pollution, which is known to affect health and indoor air quality. The research was limited to Chinese women in Taiwan and Hong Kong using traditional cooking methods, raising questions about applicability to other ethnic groups and high-income countries.
DISCLOSURES:
This study was supported by a grant from the Wellcome Trust. The National Institute for Health and Care Research Leicester Biomedical Research Centre provided additional support. The authors declared having no relevant conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scientific American
2 hours ago
- Scientific American
Could China's New GLP-1 Drugs Beat Out Ozempic?
A drug that outperforms placebo in helping people to lose weight is one of a growing number of next-generation obesity drugs being produced in China. At first, Chinese pharmaceutical companies rushed to make similar versions of blockbuster weight-loss drugs, such as Wegovy and Ozempic, that have taken the world by storm. Nowadays, China is emerging as important innovator for new drug discovery in this field, says Daniel Drucker, an endocrinologist at the University of Toronto in Canada. Results from a phase III trial of ecnoglutide show that people receiving a weekly injection of the drug lost up to 13.8 kilograms over 48 weeks of treatment. By contrast, people given placebo injections lost around 200 grams. The results were published in The Lancet Diabetes and Endocrinology on 21 June. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. Ecnoglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist analogue, similar to the blockbuster obesity drug semaglutide. These drugs mimic the hormone GLP-1, which is involved in regulating appetite and managing blood-sugar levels. Unlike semaglutide, ecnoglutide preferentially targets the production of cyclic adenosine monophosphate, a messenger molecule associated with regulating glycogen, sugar and lipid metabolism, which helps to control blood-sugar levels, as well as weight loss. The study, funded by drug manufacturer Sciwind Biosciences, based in Hangzhou, China, included 664 people given either a weekly injection of a placebo, or one of three doses of ecnoglutide. At the maximum dose of 2.4 milligrams, 92.8% of people lost at least 5% of their body weight, compared with 14% of people receiving placebo injections. People receiving ecnoglutide were also able to maintain their reduced weight after stopping treatment, regaining around 1% of their body weight over a 7-week period. Linong Ji, a co-author and a diabetes researcher at Peking University People's Hospital in Beijing, says ecnoglutide also improved risk factors for heart disease and diabetes, and reduced the amount of fat in people's livers. More drugs to come Dozens of GLP-1 drugs are being developed and tested in China, with 'many more to come', says Drucker. Among them is mazdutide, which mimics GLP-1 and glucagon, a hormone involved in blood-sugar levels. In trial results published in May, a weekly injection helped more people to lose up to 15% of their body weight over 36 weeks and reduced the risk of cardiovascular diseases compared with a placebo treatment. Developed by Eli Lilly in Indianapolis, Indiana, mazdutide is manufactured by Innovent Biologics in Suzhou, China, under an exclusive licence. Other trials are testing whether the drug can treat sleep apnoea or type 2 diabetes. The growing number of new GLP-1 drugs target multiple pathways at the same time so will result in more-tailored treatments, says Sof Andrikopoulos, a diabetes researcher at the University of Melbourne. The next generation of drugs will target specific conditions associated with diabetes and obesity, such as sleep apnoea, fatty liver disease, chronic kidney disease and heart disease, he adds. 'It'll give us options and it will make personalized medicine in obesity and diabetes more accessible.' Triple threat Another drug being developed in China, known as UBT251, is a triple agonist, mimicking GLP-1, glucagon and another hormone called gastric inhibitory polypeptide (GIP), which is involved in fat metabolism. UBT251 is the first biweekly injectable GLP-1 medicine and is in the early stages of testing to achieve weight loss and treat chronic kidney disease, fatty liver disease and type 2 diabetes. In March, Hengqin-based manufacturer the United Laboratories entered into a US$2-billion deal with Danish firm Novo Nordisk, which developed semaglutide, giving Novo Nordisk exclusive rights to test and sell the drug outside the Chinese mainland, Hong Kong, Macau and Taiwan. Bofanglutide, developed by Gan & Lee Pharmaceuticals in Beijing, is another biweekly injectable treatment, but it targets only GLP-1. A phase II trial began enrolling US participants with obesity in March to test it against a placebo and tirzepatide — sold as Mounjaro and Zepbound by Eli Lilly. Andrikopoulos says it makes sense that China is developing these drugs. 'Obesity and diabetes are major problems in Asian populations in China and in India,' he says. Studies that recruit participants in China are also important for investigating the efficacy of GLP-1 drugs in Asian populations, which could reveal differences not observed in studies from Europe or the United States. A Hong Kong-based pharmaceutical company, Ascletis, is also investigating the benefit of once-daily oral drug, called ASC30, for weight loss. Early trial results show that participants lost 6% more of their body weight on the drug than with a placebo. The company has applied for permission from the US Food and Drug Administration to run a phase II trial. Novo Nordisk and Eli Lilly are also working on oral GLP-1 medicines.
Business Upturn
17 hours ago
- Business Upturn
Acesis Biomed Secures Patents Advancing Testosterone-Inducing Drug Development
Centennial, Colorado, June 30, 2025 (GLOBE NEWSWIRE) — Acesis Holdings Corporation ('Acesis Biomed'), a pre-clinical stage biomedical company pioneering oral treatments for metabolic and endocrine disorders linked to low testosterone, today announced a meaningful expansion of its intellectual property portfolio with the granting of two patents supporting the development of its novel treatment for low testosterone. The United States Patent and Trademark Office has issued U.S. Patent No. 12324839, effective June 10, 2025, with a notable 380-day term extension. Additionally, Chinese Patent No. ZL2019800872788 was granted on June 6, 2025, strengthening Acesis's global presence and international protection for its novel drug candidates. The milestone coincides with Men's Health Month, underscoring the company's focus on advancing solutions for hormone-related health conditions. Testosterone deficiency, or low T, affects millions of men globally and is increasingly recognized not only for its impact on energy and libido, but also for its role in serious chronic conditions such as obesity, type 2 diabetes, cardiovascular disease, and diminished quality of life. Despite its prevalence, current treatments often rely on hormone replacement therapies, which may not be suitable for all patients and can carry risks such as infertility. Acesis Biomed is developing a potentially first-in-class platform of oral, mechanism-based treatment designed to stimulate the body's own production of natural testosterone. This approach is designed to address a critical unmet need by potentially offering an alternative to traditional therapies. 'This patent milestone highlights our continued progress and commitment to scientific innovation and strengthens the value of our emerging therapeutic pipeline,' said Costas Karatzas, PhD, Co-founder and CEO of Acesis Biomed. 'Testosterone deficiency remains widely underdiagnosed and an undertreated condition in men. Furthermore, this achievement, especially during Men's Health Month, reaffirms our mission to provide safe, effective novel treatments that improve health outcomes for men worldwide with low T.' With a growing awareness of the risks associated with untreated low T, Acesis Biomed offers both patients and investors a compelling opportunity at the forefront of men's health innovation. Acesis is currently raising capital through a Regulation CF Crowdfunding (RegCF) campaign to support the advancement of its proprietary oral drug candidates. For more details and to join the campaign, visit: About Acesis Biomed Acesis Holdings Corporation ('Acesis Biomed' or the 'Company') is a pre-clinical biomedical company developing a pipeline of oral drug candidates targeting metabolic and endocrine disorders associated with testosterone deficiency (low T). With an initial focus on male hypogonadism, Acesis is committed to improving outcomes across multiple co-morbidities of low-T, including type 2 diabetes, obesity, and non-alcoholic fatty liver disease. Find out more at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Miami Herald
a day ago
- Miami Herald
Owls inspire new revolutionary noise reduction technology
By Stephen Beech Owls have inspired new noise reduction technology. The silent flight of the aerial predators is possible because their skin and feathers dampen sound by absorbing high- and low-frequency flight noise. Inspired by that natural soundproofing, Chinese scientists have developed a two-layer aerogel that mimics the structures inside owl feathers and skin to reduce sound pollution. They say the new material could be used in cars and manufacturing facilities to reduce traffic and industrial noise. Previous research has shown that excessive noise can cause hearing loss and can worsen health conditions, including heart disease and type 2 diabetes. While eliminating the source of noise pollution isn't feasible, soundproofing materials help dampen it. But traditional materials absorb either high-frequency sounds, such as squealing brakes, or low-frequency sounds, like the deep rumbling of a car engine. That means engineers often layer multiple types of soundproofing materials to achieve full-spectrum noise control, which adds weight and bulk. To overcome the issue, researchers at Tiangong University in China turned to owls for inspiration. Study leader Dr. Dingding Zong said, "The owl uses its soft feathers and porous skin to remain whisper-quiet during flight." The researchers' goal was to engineer a similarly versatile broadband sound absorber. The team froze droplets of hexane into a layer of soft material, using a technique called emulsion-templated freeze-reconstruction. Dr. Zong said removing the frozen hexane revealed a honeycomb-like pattern in the material. The researchers then added a second layer with silicon nanofibres instead of hexane droplets to create a fibrous pattern. Dr. Zong said, "The resulting light, porous two-layer aerogel mimics the structures in owl skin and feathers. "The bottom porous layer resembles the bird's skin with microscopic cavities that cancel out low-frequency noise; and the top feather-inspired layer, made of fluffy nanofibres, dampens high-frequency sounds." The findings, published in the journal ACS Applied Materials and Interfaces, showed that the owl-inspired aerogels can absorb 58% of sound waves that strike it, surpassing the threshold for effective noise control materials. The researchers also found that the aerogels reduce 87.5 decibels of automobile engine noise to a safe level of 78.6 decibels, which is a better reduction than existing high-end noise absorbers. The researchers believe the study paves the way for high-performance, lightweight and durable sound-absorbing materials that can "significantly alleviate" noise pollution from industrial equipment and traffic. The post Owls inspire new revolutionary noise reduction technology appeared first on Talker. Copyright Talker News. All Rights Reserved.
